Clinical trial
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma…
NCT00156013 · Oncology Specialists, S.C., Other · Completed
Key facts
| NCT number | NCT00156013 |
|---|---|
| Title | Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) |
| Official title | A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL |
| Lead sponsor | Oncology Specialists, S.C., Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | CLOFARABINE |
| Enrollment | 33 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Sep 12, 2005 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: